Harnessing the power of RNA modification

Watch full video

1st in Class Inhibitors of RNA Modifying Enzymes (RME) to Treat Cancer and Other Diseases

STORM Therapeutics is a clinical stage biotechnology company, creating novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. There are more than 150 RNA modifications reported and approximately 300 RNA modifying enzymes which represent novel therapeutic targets.

Read more

RNA modifying enzymes

RNA (ribonucleic acid) is the only direct product of the human genome and one type of RNA, mRNA, acts as the template to which transfer RNAs (tRNA) bind to drive the synthesis of all proteins, the molecular machines of the cell. RNA is also known to be a key player in cellular decision-making, particularly in the form of non-coding RNA (ncRNA) such as microRNA, piRNA and long non-coding RNA.

Read more


STORM Therapeutics doses first patient with oral METTL3 targeting drug candidate in a solid tumor Phase 1 study

STORM Therapeutics to present new data on its lead program STC-15 at the 34th EORTC-NCI-AACR Symposium and the 37th SITC Meeting


7 - 9th December 2022 | Switzerland


23 - 25th January 2023 | Austin, Texas

American Association for Cancer Research (AACR) Special Conference, Acute Myeloid Leukemia and Myelodysplastic Syndrome